Northland Capital Markets Maintains Outperform on Cardlytics, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Northland Capital Markets analyst Luke Horton maintains an Outperform rating on Cardlytics (NASDAQ:CDLX) but lowers the price target from $14 to $7.
August 08, 2024 | 5:25 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Northland Capital Markets maintains an Outperform rating on Cardlytics but lowers the price target from $14 to $7.
The lowered price target from $14 to $7 suggests a more cautious outlook on Cardlytics' future performance, which could negatively impact short-term investor sentiment despite the maintained Outperform rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100